CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 313 enrolled
Drug / intervention
Mometasone furoate +3 moredrug
Likely dose
Mometasone furoate 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03882047
NCT03882047Phase 3Completed

Efficacy and Safety of Mometasone Furoate Aqueous Nasal Spray vs Placebo and Flonase® (Fluticasone Propionate) in Seasonal Allergic Rhinitis Patients (I94-001)

Organon and Co·interventional·Posted Mar 20, 2019·Updated Feb 9, 2022

In Brief

A Phase 3 clinical trial evaluating Mometasone furoate, Fluticasone propionate, and 2 other interventions for Rhinitis, Allergic, Seasonal. Completed, enrolled 313 participants.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of mometasone furoate (SCH 32088) aqueous nasal spray 200 mcg once daily compared to placebo once daily in the treatment of participants with seasonal allergic rhinitis. Flonase (fluticasone propionate) nasal spray 200 mcg once daily has been chosen as the active control for this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 20, 2019
Enrollment StartAug 11, 1994
Primary CompletionSep 16, 1994
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.3 years ago

Interventions

Mometasone furoatedrug

Mometasone furoate nasal spray, 200 mg once daily

Fluticasone propionatedrug

Fluticasone propionate nasal spray, 200 mg once daily

Mometasone furoate placebodrug

Mometasone furoate placebo matching nasal spray, once daily

Fluticasone propionate placebodrug

Fluticasone propionate placebo matching nasal spray, once daily